Flag of the European Union EU Clinical Trials Register Help

Clinical trials for vaccine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,995 result(s) found for: vaccine. Displaying page 25 of 100.
    «« First « Previous 21  22  23  24  25  26  27  28  29  Next» Last»»
    EudraCT Number: 2020-004123-16 Sponsor Protocol Number: 2019nCoV-302 Start Date*: 2020-09-23
    Sponsor Name:Novavax, Inc.
    Full Title: A Phase 3, Randomised, Observer-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) with Matrix-M1™ ...
    Medical condition: Prevention of COVID-19 caused by SARS-CoV-2
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-002537-37 Sponsor Protocol Number: 114858 Start Date*: 2015-07-23
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IIIb, open, multi-country, controlled, randomized study to demonstrate the immunogenicity and safety of GSK Biologicals' meningococcal conjugate vaccine, MenACWY-TT (GSK 134612) in healthy ...
    Medical condition: Active immunisation of healthy infants to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W-135 and Y
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-000290-20 Sponsor Protocol Number: 204889 Start Date*: 2017-09-22
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: Phase IIb randomized, open-label, controlled, multi-center study of the efficacy, safety and immunogenicity of GSK Biologicals’ candidate malaria vaccine RTS,S/AS01E evaluating schedules with or wi...
    Medical condition: Healthy volunteers (primary immunization against malaria disease caused by Plasmodium falciparum)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10025487 Malaria PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-002140-27 Sponsor Protocol Number: 112909 Start Date*: 2012-04-12
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, open study in children previously enrolled in study 10PN-PD-DIT-037 (111188) to assess the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pne...
    Medical condition: Healthy volunteers (Vaccination against Streptococcus pneumoniae in healthy children previously enrolled in study 10PN-PD-DIT-037 (111188).)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10061353 Pneumococcal infection PT
    14.1 10021881 - Infections and infestations 10061190 Haemophilus infection PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-003277-55 Sponsor Protocol Number: CAR-CF Start Date*: 2021-09-01
    Sponsor Name:Medical University of Innsbruck, University Clinic for Pediatrics III
    Full Title: COVID-19 Antibody Responses in Cystic Fibrosis: CAR-CF
    Medical condition: COVID-19 vaccine Antibody response from natural infection or after vaccination in patients with Cystic Fibrosis (CF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10021433 Immunization LLT
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002927-39 Sponsor Protocol Number: BOOST_TX/RESCUE_TX Start Date*: 2021-06-13
    Sponsor Name:Medical University of Vienna
    Full Title: Preventive strategies against SARS-CoV-2 in kidney transplant recipients: Intervention A – vaccination: Single blinded randomized controlled trial on BNT162b2 or mRNA-1273 (mRNA) vs Ad26COVS1 or C...
    Medical condition: Intervention A - vaccination Patients following kidney transplant recipients who do not have an adequate immune response against SARS-CoV-2 following two doses of an mRNA vaccine Substudy A: kidne...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002871-15 Sponsor Protocol Number: V58P13 Start Date*: 2007-09-14
    Sponsor Name:Novartis Vaccines and Diagnostics S.r.l.
    Full Title: A Phase III, Randomized, Observer-Blind, Placebo-Controlled, Multicenter Study to Assess Clinical Efficacy of a Cell-Derived Subunit Influenza Vaccine and an Egg-Derived Subunit Influenza Vaccine i...
    Medical condition: Influenza disease.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2006-003815-31 Sponsor Protocol Number: 108708 Start Date*: 2006-10-05
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IIb, controlled, randomized, multicenter, observer blinded study to evaluate the immunogenicity, safety and reactogenicity of a second vaccination with the low dose influenza vaccine adjuva...
    Medical condition: Re-vaccination against influenza in male and female subjects aged 60 years and older.
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: View results
    EudraCT Number: 2011-002077-35 Sponsor Protocol Number: 111634 Start Date*: 2012-04-12
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, open, controlled study in South Africa to assess the immunogenicity, safety and reactogenicity of GSK Biologicals’ 10-valent pneumococcal conjugate vaccine administered as a 3-dose (6,...
    Medical condition: 3- or 2-dose primary vaccination against Streptococcus pneumoniae together with a 3-dose primary vaccination against diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b di...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10061353 Pneumococcal infection PT
    14.1 10021881 - Infections and infestations 10061190 Haemophilus infection PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-001713-26 Sponsor Protocol Number: CYD28 Start Date*: 2014-05-26
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Large-Scale Safety of Tetravalent Dengue Vaccine in Healthy Subjects Aged 2 to 45 Years in Singapore
    Medical condition: Prevention of symptomatic dengue disease
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-005036-33 Sponsor Protocol Number: M37P1 Start Date*: 2014-11-18
    Sponsor Name:Novartis Vaccines and Diagnostics
    Full Title: A phase I study to investigate safety and reactogenicity of Vaxem Hib in healthy children aged 16 – 20 months and infants aged 2 - 4 months.
    Medical condition: Meningitis, epiglottitis, pneumonia, arthritis caused by Haemophilus influenzae type b.
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-001737-88 Sponsor Protocol Number: CYD57 Start Date*: 2014-05-26
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Long-Term Safety Follow-Up of Thai Children Who Were Included in an Efficacy Study of a Tetravalent Dengue Vaccine
    Medical condition: Prevention of symptomatic dengue disease
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-001422-14 Sponsor Protocol Number: CSLCT-NHF-07-49 Start Date*: 2008-04-29
    Sponsor Name:CSL Limited
    Full Title: A Single Centre, Open-Label Study to Evaluate the Immunogenicity and Safety of Enzira® vaccine in Healthy ‘Adults’ aged ≥ 18 to < 60 years and in Healthy ‘Older Adults’ aged ≥ 60 years for the 2008...
    Medical condition: Prophylaxis of influenza
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-001715-39 Sponsor Protocol Number: CYD30 Start Date*: 2014-05-26
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America
    Medical condition: Prevention of symptomatic dengue disease
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-003138-26 Sponsor Protocol Number: 58746 Start Date*: 2016-10-04
    Sponsor Name:LUMC
    Full Title: Influenza vaccination in patients with Myasthenia Gravis
    Medical condition: Myasthenia gravis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003054-24 Sponsor Protocol Number: B1851172 Start Date*: 2019-04-16
    Sponsor Name:Pfizer Inc.
    Full Title: A Phase 3, Multicenter, Single-arm, Open-label Study To Assess The Safety, Tolerability, And Immunogenicity Of A Single Dose Of 13-valent Pneumococcal Conjugate Vaccine In Japanese Subjects Aged 6 ...
    Medical condition: Pneumococcal Infections
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-004833-17 Sponsor Protocol Number: CBD VP 128/05 Start Date*: 2009-05-01
    Sponsor Name:Dstl
    Full Title: Assessment of the effect of prior anthrax vaccine precipitated (AVP) vaccination on the immune response to booster AVP vaccination.
    Medical condition: Vaccination against potential exposure to anthrax (Bacillus anthracis).
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004131-40 Sponsor Protocol Number: CSLCT-USF-06-29 Start Date*: 2015-01-08
    Sponsor Name:CSL Limited
    Full Title: A Phase IV, Open Label, Multi-Centre Study to Evaluate the Safety and Tolerability of CSL Limited's Influenza Virus Vaccine in a paediatric population aged greater than or equal to 6 months to less...
    Medical condition: Influenza, human
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-000254-64 Sponsor Protocol Number: 114056 Start Date*: 2012-04-12
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, open, controlled study to evaluate the immunogenicity, safety and reactogenicity of GSK Biologicals’ 10- valent pneumococcal conjugate vaccine administered to children with sickle cell...
    Medical condition: Active immunization against disease caused by Streptococcus pneumoniae in children from 8 weeks up to 2 years of age.
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10061190 Haemophilus infection PT
    17.1 10021881 - Infections and infestations 10061353 Pneumococcal infection PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-005187-42 Sponsor Protocol Number: IPV35_EFC12403 Start Date*: 2015-11-19
    Sponsor Name:Sanofi Aventis K.K.
    Full Title: Immunogenicity and Safety of the SP059 Given Subcutaneously as a Three-Dose Primary and Booster Vaccination in Infants in Japan
    Medical condition: Poliomyelitis
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 21  22  23  24  25  26  27  28  29  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 30 00:38:57 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA